Parnell Pharmaceuticals Holdings Ltd Announces Proposed Rights Offering

Rhea-AI Summary

Parnell Pharmaceuticals Holdings Ltd (PARNF) announced a $4.0 million backstopped rights offering for qualifying shareholders, set to occur on December 6, 2022. The offering allows shareholders to purchase shares at $0.075 each, between December 6, 2022, and January 5, 2023. DW Healthcare Partners will backstop the offering, ensuring all shares are purchased if not fully subscribed. This offering is not registered with the SEC and will occur under private placement regulations.

Positive

• Rights offering will raise $4.0 million for the company.
• DW Healthcare Partners fully backstopping the offering provides financial assurance.

Negative

• The need for a rights offering may indicate financial distress or operational challenges.

SYDNEY, Dec. 1, 2022 /PRNewswire/ -- Parnell Pharmaceuticals Holdings Ltd (OTC Pink^® Open Market: PARNF) ("Parnell") announced its intention to raise US$4.0 million through a backstopped rights offering at no charge (the "Rights Offering") for qualifying shareholders of record as of December 6, 2022 (the "Record Date"). The Rights Offering will be fully backstopped by existing investors DW Healthcare Partners V, L.P. and DW Healthcare Affiliates V, L.P. (collectively, "DW Healthcare Partners") subject to the terms and conditions of the backstop agreement as more fully described in the offering circular issued in connection with the Rights Offering on December 6, 2022 (the "Offering Circular").

Under the proposed Rights Offering, Parnell plans to distribute to qualifying shareholders on the Record Date non-transferable subscription rights entitling the holder of such right to subscribe for a fixed number of Parnell's ordinary shares of common stock ("Ordinary Shares") at a subscription price per share of US$0.075. The subscription rights may be exercised only during the anticipated subscription period of Tuesday, December 6, 2022 through 5:00 PM (Eastern Time) on Thursday, January 5, 2023 (subject to any extension or cancellation on the terms of the Offering Circular).

Subject to the terms and conditions of the backstop agreement, DW Healthcare Partners will backstop the Rights Offering and has agreed to purchase all the Ordinary Shares that are not subscribed for by other shareholders of Parnell at the same subscription price under the Rights Offering, US$0.075.

The securities described above will be offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Act"), and Regulation D promulgated thereunder and have not been registered under the Act or applicable state securities laws. Accordingly, such securities may not be offered or sold in the United States absent registration with the Securities and Exchange Commission ("SEC") or an applicable exemption from such registration requirements.

This press release is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities in any jurisdiction, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law or regulation.

About Parnell Pharmaceuticals Holdings Ltd

Parnell is a fully integrated, veterinary pharmaceutical company focused on developing, manufacturing and commercializing innovative animal health solutions. We currently manufacture and market five products for companion animals and production animals in 10 countries and augment our production animal pharmaceutical products with proprietary software platform mySYNCH^®.

A copy of this press release can be found on Parnell's website at http://www.parnell.com. 

Forward Looking Statements

This press release includes "forward-looking statements" within the meaning of the U.S. federal securities laws. Statements contained herein that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "continues," "expect," "estimate," "intend," "project" and similar expressions and future or conditional verbs such as "will," "would," "should," "could," "might," "can," "may," or similar expressions are generally intended to identify forward-looking statements. These forward-looking statements speak only as of the date hereof and are based on Parnell's current plans, estimates of future events, expectations and trends that affect or may affect our business, financial condition, results of operations, cash flow, liquidity, prospects and the trading price of Parnell's common shares, and are subject to several known and unknown uncertainties and risks, many of which are beyond Parnell's control. As a consequence, current plans, anticipated actions and future financial position and results of operations may differ significantly from those expressed in any forward-looking statements in this press release. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented. Parnell does not undertake any obligation to update publicly or to revise any forward-looking statements after we distribute this press release because of new information, future events, or other factors.

View original content:https://www.prnewswire.com/news-releases/parnell-pharmaceuticals-holdings-ltd-announces-proposed-rights-offering-301692174.html

SOURCE Parnell Pharmaceuticals Holdings Ltd

FAQ

What is the purpose of Parnell Pharmaceuticals' rights offering announced on December 1, 2022?

Parnell's rights offering aims to raise $4.0 million for its operations.

Who is backing Parnell Pharmaceuticals' rights offering?

The offering is fully backstopped by DW Healthcare Partners.

When can shareholders participate in the rights offering for Parnell Pharmaceuticals?

Shareholders can subscribe from December 6, 2022, to January 5, 2023.

What is the subscription price for Parnell Pharmaceuticals' rights offering?

The subscription price is set at $0.075 per share.

What will happen if not all shares are subscribed in Parnell Pharmaceuticals' offering?

DW Healthcare Partners will purchase any remaining shares.